Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, shares his excitement for the upcoming results of the GMMG HD7 trial which will assess whether the differences in measurable residual disease (MRD) negativity observed in patients with newly diagnosed multiple myeloma (NDMM) treated with isatuximab, lenalidomide, bortezomib and dexamethasone (Isa-RVd) and patients treated with RVd alone translate in an improved progression-free survival (PFS), and will also compare the efficacy of isatuximab-lenalidomide vs lenalidomide maintenance therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
